Aaron’s Company to be Acquired by IQVentures Holdings for $504 Million in Cash

 Lease-to-own furniture retailer Aaron’s Company, Inc. (AAN) entered into a definitive agreement on June 17, 2024, with fintech firm IQVentures Holdings, LLC,  to be acquired for an enterprise value of about $504 million.

Deal Structure:

Under this agreement, IQVentures will acquire Aaron’s Company at a purchase price of $10.10 per share in cash, representing a premium of 33.95% from the stock’s last close.

Company Profile:

Headquartered in Atlanta, The Aaron’s Company, Inc. provides lease-to-own and retail purchase solutions for home goods through its brands—Aaron’s, BrandsMart U.S.A, BrandsMart Leasing, and Woodhaven—via 1,220 stores in 47 states and Canada, and online.

IQVentures is based in the Columbus, Ohio area, and invests in and builds future-shaping technology companies, leveraging its expertise in consumer and business financing and proprietary technology to drive value.

Deal Details and Timeline:

Upon completion of the transaction, which is expected to close by the end of the year, Aaron’s Company will become a privately held company.

Aaron’s current EV/EBITDA (TTM) ratio is 5.29, below the sector median of 10.61.

After the transaction closes, The Aaron’s Company will retain its existing brand names and continue to be headquartered in Atlanta, Georgia.

Deal Metrics:

For a deeper understanding of this merger and acquisition transaction, you are encouraged to visit the Deal Metrics page at this link:

Deal Metrics for the acquisition of Aaron’s Company, Inc. (AAN) by IQVentures Holdings, LLC

The Deal Metrics page for each merger or acquisition includes:

  • A spread history chart of the merger from announcement through eventual completion or failure.
  • Progress report of the merger covering the HSR period, regulatory approvals, shareholder votes, etc.
  • News and SEC filings.
  • A history of deal updates.
  • And much more useful information.
Disclaimer: Please ensure that you carry out your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Comments

Post a Comment

Popular posts from this blog

Strategic Biopharma Merger: Pharmacosmos to Acquire G1 Therapeutics in $405M Deal

  In the ever-evolving landscape of the biopharmaceutical industry, strategic acquisitions and mergers are critical for companies looking to bolster their portfolios and expand their global reach. Last week, we witnessed a noteworthy development as G1 Therapeutics Inc. (NASDAQ: GTHX) became the latest target in a high-profile acquisition by Pharmacosmos A/S, a Denmark-based company renowned for its expertise in carbohydrate chemistry and treatments for iron deficiency and anemia. Read More Info @ https://www.insidearbitrage.com/2024/08/g1-therapeutics-attracts-a-danish-suitor-merger-arbitrage-mondays/ The Deal in Detail Pharmacosmos, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., has entered into a definitive merger agreement to acquire G1 Therapeutics for a total deal size of approximately $405 million. This transaction represents a significant premium over G1's market value, offering $7.15 per share in cash, which is a substantial 68.24% premium over G1’s las...
Read more

The Landos Biopharma Acquisition: AbbVie’s $137.5M Deal Includes a Significant CVR

  The pharmaceutical industry continues to witness strategic acquisitions, with the latest being AbbVie’s (ABBV) acquisition of Landos Biopharma (LABP) . This deal, valued at $137.5 million, not only highlights the ongoing interest in innovative biotech firms but also features a substantial contingent value right (CVR) that could significantly enhance shareholder value. Key Details of the Acquisition: ·          Deal Structure : AbbVie is acquiring Landos Biopharma for $20.42 per share in an all-cash transaction. ·          CVR Potential : The deal includes a potential CVR payment of $11.14 per share, bringing the total potential value per share to $31.56. ·          Total Valuation : Without considering the CVR, the deal is valued at $90.65 million. However, if the CVR conditions are met, the total value could reach $137.5 million. ·    ...
Read more

Darden's Bold Move: Acquiring Chuy's for a Flavorful Future

  In the latest shake-up in the restaurant industry, Darden Restaurants, Inc. has announced its acquisition of Chuy's Holdings, Inc . This merger is set to create a powerhouse in the casual dining sector, bringing together two beloved brands under one corporate roof. Here’s what you need to know about this exciting development. Chuy’s Holdings Inc. ( CHUY ):  $37.08 Market Cap:  $643.38 M Deal Size:  $605 M Back in 2014, a heated battle between Darden Restaurants  (DRI)  and the activist hedge fund Starboard Value brought to light some surprising inefficiencies within Darden’s flagship chain, Olive Garden. In an attempt to win control of Darden’s board, Starboard pointed out not only the wastefulness of unlimited breadsticks at Olive Garden but also its puzzling decision to stop salting its pasta water as “adding salt to the boiling water could jeopardize warranties on pots”. These small yet significant details became symbols of the broader issues w...
Read more